Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Cynara scolymus (Cynarin).
Cynarin acts as a potent choleretic and hepatoprotective agent by stimulating bile acid secretion and inhibiting HMG-CoA reductase to modulate lipid metabolism and alleviate dyspeptic symptoms.
5281769
516.4 g/mol
1.5
(1R,3R,4S,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxycyclohexane-1-carboxylic acid
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Cynara scolymus (Cynarin) across standard consumer modalities.
The hygroscopic nature of concentrated artichoke extracts requires moisture-resistant HPMC shells and desiccants to prevent powder clumping and oxidative degradation.
High organic acid content and inherent bitterness necessitate precise pH buffering to prevent pectin hydrolysis and complex masking agents to offset the astringent profile.
The high therapeutic dose required for clinical efficacy typically exceeds the standard 50mg payload capacity of thin-film polymer matrices.
Ready to launch a product featuring Cynara scolymus (Cynarin)? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Cynara scolymus (Cynarin) extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Cynara scolymus (Cynarin) payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation